MARKET

ARDX

ARDX

Ardelyx
NASDAQ
3.410
-0.010
-0.29%
After Hours: 3.437 +0.027 +0.79% 17:56 09/28 EDT
OPEN
3.400
PREV CLOSE
3.420
HIGH
3.440
LOW
3.375
VOLUME
3.32M
TURNOVER
--
52 WEEK HIGH
8.40
52 WEEK LOW
3.330
MARKET CAP
849.73M
P/E (TTM)
-15.0818
1D
5D
1M
3M
1Y
5Y
1D
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Barchart · 6d ago
Ardelyx (ARDX) Investors File Securities Lawsuit After 18% Stock Drop Over Alleged Drug Revenue and Payer Disclosures
TipRanks · 6d ago
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Barchart · 09/21 20:22
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
PR Newswire · 09/21 15:12
ARDX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Ardelyx, Inc.
Barchart · 09/21 14:13
Weekly Report: what happened at ARDX last week (0914-0918)?
Weekly Report · 09/21 09:12
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX
Barchart · 09/21 06:30
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Barchart · 09/19 13:49
More
About ARDX
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.

Webull offers Ardelyx Inc stock information, including NASDAQ: ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.